Supernus Pharmaceuticals Inc

NASDAQ:SUPNUnited States

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Contact Information

Headquarters

9715 Key West AvenueROCKVILLE, MD, United States 20850

Phone

301-838-2500

Fax

302-636-5454

Executives

Independent Chairman of the Board

Charles Newhall

President, Chief Executive Officer, Secretary, Director

Jack Khattar

Chief Financial Officer, Senior Vice President

Timothy Dec

Senior Vice President - Intellectual Property, Chief Scientific Officer

Padmanabh Bhatt

Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs

Frank Mottola